Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue SUPPL. 1, 2013, Pages

  Spur, Eva Margarete ^a,b   Decelle, Emily A ^a   Cheng, Leo L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Magnetic resonance spectroscopy; Mass spectrometry; Metabolomic imaging; Metabolomics; Prostate cancer

Indexed keywords

ANATOMICAL VARIATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER TISSUE; EX VIVO STUDY; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; MALE; METABOLISM; METABOLOME; PROSTATIC NEOPLASMS; PROSTATE TUMOR;

HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; METABOLOME; PROSTATIC NEOPLASMS;

EID: 84891605109     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2379-x     Document Type: Review

References (67)

1. National Cancer Institute. Defeating prostate cancer: crucial directions for research, report of the prostate cancer progress review group. Bethesda, MD: National Cancer Institute; 1998.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
3. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Mortality results from a randomized prostatecancer screening trial. N Engl J Med. 2009;360:1310-9.
4. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986- 2005. J Natl Cancer Inst. 2009;101:1325-9.
5. Brawer MK. Prostate-specific antigen: current status. CA Cancer J Clin. 1999;49:264-81.
6. Brawer MK. Prostate-specific antigen. Semin Surg Oncol. 2000;18:3-9.
7. Loeb S, Catalona WJ. Prostate-specific antigen screening: pro. Curr Opin Urol. 2010;20:185-8.
8. Andriole GL, Crawford ED, Grubb 3rd RL, Buys SS, Chia D, Church TR, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2011;104:125-32.
9. Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2010;29:593-601.
10. Loeb S, Roehl KA, Helfand BT, Kan D, Catalona WJ. Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? J Urol. 2010;183:112-6.
11. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep. 2010;11:165-71.
12. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320-8.
13. Cheng LL, Pohl U. The role of NMR-based metabolomics in cancer. In: Lindon JC, Nicholls JK, Holmes E, editors. The handbook of metabonomics and metabolomics. Amsterdam: Elsevier; 2007. p. 345-74.
14. Trock BJ. Application of metabolomics to prostate cancer. Urol Oncol. 2011;29:572-81.
15. Lodi A, Ronen SM. Magnetic resonance spectroscopy detectable metabolomic fingerprint of response to antineoplastic treatment. PLoS One. 2011;6:e26155.
16. Teahan O, Bevan CL, Waxman J, Keun HC. Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol. 2011;43:1002-9.
17. Teichert F, Verschoyle RD, Greaves P, Edwards RE, Teahan O, Jones DJ, et al. Metabolic profiling of transgenic adenocarcinoma of mouse prostate (TRAMP) tissue by 1H-NMR analysis: evidence for unusual phospholipid metabolism. Prostate. 2008;68:1035-47.
18. Raina K, Ravichandran K, Rajamanickam S, Huber KM, Serkova NJ, Agarwal R. Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: a multiparametric magnetic resonance study. Cancer Prev Res (Phila). 2013;6:40-50.
19. Chaurand P, Rahman MA, Hunt T, Mobley JA, Gu G, Latham JC, et al. Monitoring mouse prostate development by profiling and imaging mass spectrometry. Mol Cell Proteomics. 2008;7:411-23.
20. Wu H, Liu T, Ma C, Xue R, Deng C, Zeng H, et al. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwaveassisted derivatization. Anal Bioanal Chem. 2011;401:635-46.
21. Saylor PJ, Karoly ED, Smith MR. Prospective study of changes in the metabolomic profiles of men during their first three months of androgen deprivation therapy for prostate cancer. Clin Cancer Res. 2012;18:3677-85.
22. Fan Y, Murphy TB, Byrne JC, Brennan L, Fitzpatrick JM, Watson RW. Applying random forests to identify biomarker panels in serum 2D-DIGE data for the detection and staging of prostate cancer. J Proteome Res. 2011;10:1361-73.
23. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6: e24143.
24. Cheng LL, Lean CL, Bogdanova A, Wright Jr SC, Ackerman JL, Brady TJ, et al. Enhanced resolution of proton NMR spectra of malignant lymph nodes using magic-angle spinning. Magn Reson Med. 1996;36:653-8.
25. Cheng LL, Ma MJ, Becerra L, Ptak T, Tracey I, Lackner A, et al. Quantitative neuropathology by high resolution magic angle spinning proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 1997;94:6408-13.
26. Cheng LL, Chang IW, Louis DN, Gonzalez RG. Correlation of high-resolution magic angle spinning proton magnetic resonance spectroscopy with histopathology of intact human brain tumor specimens. Cancer Res. 1998;58:1825-32.
27. Burns MA, He W, Wu CL, Cheng LL. Quantitative pathology in tissue MR spectroscopy based human prostate metabolomics. Technol Cancer Res Treat. 2004;3:591-8.
28. Smith R, Litwin M, Lu Y, Zetter B. Identification of an endogenous inhibitor of prostate carcinoma cell growth. Nat Med. 1995;1:1040-5.
29. Franklin RB, Feng P, Milon B, Desouki MM, Singh KK, Kajdacsy-Balla A, et al. hZIP1 zinc uptake transporter down regulation and zinc depletion in prostate cancer. Mol Cancer. 2005;4:32.
30. Dittrich R, Kurth J, Decelle EA, Defeo EM, Taupitz M, Wu S, et al. Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis. 2012;15:278-82.
31. Swanson MG, Zektzer AS, Tabatabai ZL, Simko J, Jarso S, Keshari KR, et al. Quantitative analysis of prostate metabolites using 1H HRMAS spectroscopy. Magn Reson Med. 2006;55:1257-64.
32. Swanson MG, Keshari KR, Tabatabai ZL, Simko JP, Shinohara K, Carroll PR, et al. Quantification of choline- and ethanolaminecontaining metabolites in human prostate tissues using 1H HRMAS total correlation spectroscopy. Magn Reson Med. 2008;60:33-40.
33. Swanson MG, Vigneron DB, Tabatabai ZL, Males RG, Schmitt L, Carroll PR, et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues. Magn Reson Med. 2003;50:944-54.
34. Cheng LL, Burns MA, Taylor JL, He W, Halpern EF, McDougal WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005;65:3030-4.
35. Wu CL, Jordan KW, Ratai EM, Shen J, Adkins CB, DeFeo EM, et al. Metabolomic imaging for human prostate cancer detection. Sci Transl Med. 2010;2:16ra8.
36. Maxeiner A, Adkins CB, Zhang Y, Taupitz M, Halpern EF, McDougal WS, et al. Retrospective analysis of prostate cancer recurrence potential with tissue metabolomic profiles. Prostate. 2010;70:710-7.
37. Burns MA, Taylor JL, Wu CL, Zepeda AG, Bielecki A, Cory D, et al. Reduction of spinning sidebands in proton NMR of human prostate tissue with slow high-resolution magic angle spinning. Magn Reson Med. 2005;54:34-42.
38. Taylor JL, Wu CL, Cory D, Gonzalez RG, Bielecki A, Cheng LL. High-resolution magic angle spinning proton NMR analysis of human prostate tissue with slow spinning rates. Magn Reson Med. 2003;50:627-32.
39. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009;457:910-4.
40. Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue. BMC Clin Pathol. 2011;11:14.
41. Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, King CR, et al. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging. 2012;36:697-703.
42. Kurhanewicz J, Vigneron DB. Advances in MR spectroscopy of the prostate. Magn Reson Imaging Clin N Am. 2008;16:697-710, ix-x.
43. Yakar D, Heijmink SW, de Kaa CA H, Huisman H, Barentsz JO, Futterer JJ, et al. Initial results of 3-dimensional 1H-magnetic resonance spectroscopic imaging in the localization of prostate cancer at 3 Tesla: should we use an endorectal coil. Invest Radiol. 2011;46:301-6.
44. Posse S, Otazo R, Dager SR, Alger J. MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging. 2012. doi:10.1002/jmri.23945.
45. Cady EB, Costello AM, Dawson MJ, Delpy DT, Hope PL, Reynolds EO, et al. Non-invasive investigation of cerebral metabolism in newborn infants by phosphorus nuclear magnetic resonance spectroscopy. Lancet. 1983;1:1059-62.
46. Hope PL, Costello AM, Cady EB, Delpy DT, Tofts PS, Chu A, et al. Cerebral energy metabolism studied with phosphorus NMR spectroscopy in normal and birth-asphyxiated infants. Lancet. 1984;2:366-70.
47. Laprie A, Pirzkall A, Haas-Kogan DA, Cha S, Banerjee A, Le TP, et al. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:20-31.
48. Nie K, Zhang Y, Huang B, Wang L, Zhao J, Huang Z, et al. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment. Parkinsonism Relat Disord. 2013;19:329-34.
49. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L, et al. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology. 2006;66:718-22.
50. Tafazoli S, O'Neill J, Bejjani A, Ly R, Salamon N, McCracken JT, et al. 1H MRSI of middle frontal gyrus in pediatric ADHD. J Psychiatr Res. 2013;47:505-12.
51. Seese RR, O'Neill J, Hudkins M, Siddarth P, Levitt J, Tseng B, et al. Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia. Schizophr Res. 2011;133:82-90.
52. Zabala A, Sanchez-Gonzalez J, Parellada M, Moreno DM, Reig S, Burdalo MT, et al. Findings of proton magnetic resonance spectometry in the dorsolateral prefrontal cortex in adolescents with first episodes of psychosis. Psychiatry Res. 2007;156:33-42.
53. Kirov II, Tal A, Babb JS, Lui YW, Grossman RI, Gonen O. Diffuse axonal injury in mild traumatic brain injury: a 3D multivoxel proton MR spectroscopy study. J Neurol. 2013;260:242-52.
54. Munoz Maniega S, Cvoro V, Chappell FM, Armitage PA, Marshall I, Bastin ME, et al. Changes in NAA and lactate following ischemic stroke: a serial MR spectroscopic imaging study. Neurology. 2008;71:1993-9.
55. Maudsley AA, Domenig C, Ramsay RE, Bowen BC. Application of volumetric MR spectroscopic imaging for localization of neocortical epilepsy. Epilepsy Res. 2010;88:127-38.
56. Kurhanewicz J, Swanson M, Nelson S, Vigneron D. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging. 2002;16(4):451-463.
57. Kurhanewicz J, Vigneron D, Hricak H, Narayan P, Carroll P, Nelson S. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology. 1996;198:795-805.
58. Scheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL, Huang LR, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology. 1999;213:473-80.
59. Yuen JS, Thng CH, Tan PH, Khin LW, Phee SJ, Xiao D, et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol. 2004;171:1482-6.
60. Mueller-Lisse UG, Swanson MG, Vigneron DB, Hricak H, Bessette A, Males RG, et al. Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn Reson Med. 2001;46:49-57.
61. Prando A, Kurhanewicz J, Borges AP, Oliveira Jr EM, Figueiredo E. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology. 2005;236:903-10.
62. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology. 1999;213:481-8.
63. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology. 2005;234:804-14.
64. Selnaes KM, Gribbestad IS, Bertilsson H, Wright A, Angelsen A, Heerschap A, Tessem MB. Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer - investigation of a correlation with Gleason score. NMR Biomed. 2012. doi:10.1002/nbm.2901.
65. Selnaes KM, Heerschap A, Jensen LR, Tessem MB, Schweder GJ, Goa PE, et al. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology. Invest Radiol. 2012;47:624-33.
66. Klomp DW, Bitz AK, Heerschap A, Scheenen TW. Proton spectroscopic imaging of the human prostate at 7T. NMR Biomed. 2009;22:495-501.
67. Cazares LH, Troyer D, Mendrinos S, Lance RA, Nyalwidhe JO, Beydoun HA, et al. Imaging mass spectrometry of a specific fragment of mitogen-activated protein kinase/extracellular signalregulated kinase kinase kinase 2 discriminates cancer from uninvolved prostate tissue. Clin Cancer Res. 2009;15:5541-51.